M. Fleur du Pre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
M. Fleur du Pre has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Ludvig M. Sollid
Norwegian Coeliac Disease Research Centre, Institute of Clinical Medicine, University of Oslo
9 shared publications - Alisa E. Dewan
Norwegian Coeliac Disease Research Centre Institute of Clinical Medicine University of Oslo Oslo Norway
4 shared publications - Christian B. Lindstad
Affiliations K.G. Jebsen Coeliac Disease Research Centre, University of Oslo, Oslo, Norway, Department of Immunology, University of Oslo, Oslo, Norway
3 shared publications - Jorunn Stamnaes
Proteomics Core Facility, Department of Immunology, Department of Clinical Medicine (KlinMed), Medical Faculty, University of Oslo (UiO) and Division of Laboratory Medicine (KLM), Oslo University Hospital (OUS), Sognsvannsveien 20, Oslo, NO-0372, Norway
3 shared publications Liv Kleppa
Norwegian Coeliac Disease Research Centre, Institute of Clinical Medicine, University of Oslo
3 shared publicationsLudvig M. Sollid
Affiliations K.G. Jebsen Coeliac Disease Research Centre, University of Oslo, Oslo, Norway, Department of Immunology, University of Oslo, Oslo, Norway, Department of Immunology, Oslo University Hospital, Oslo, Norway
3 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 15
Role of gut epithelial-cell derived transglutaminase 2 in the formation of celiac disease autoantibodies
Formation of autoantibodies to transglutaminase 2 (TG2) in celiac disease likely involves TG2-gluten complexes that allow gluten-specific CD4+ T cells to provide help to TG2-specific B cells. To investigate whether TG2 derived from intestinal epithelial cells (IECs) contributes to this process, we generated mice with inducible IEC-specific expression of TG2 fused to a deamidated gluten peptide (DGP) containing a T-cell epitope. Upon induction, the TG2-DGP fusion protein was expressed in IECs and released into the intestinal lumen. In HLA-DQ2.5 transgenic mice with activated gluten-specific CD4+ T cells and naive TG2-specific B cells, expression of TG2-DGP was immunogenic and drove the production of intestinal and systemic anti-TG2 autoantibodies. TG2-specific B cells predominantly expanded in Peyer’s patches, suggesting that their priming and subsequent differentiation into lamina propria TG2-specific IgA+ plasma cells occurs in gut-associated lymphoid tissues. The findings demonstrate immunogenicity of IEC-derived TG2-DGP fusion antigen supporting the notion of a pathogenic role for luminal TG2 in driving anti-TG2 autoimmunity in celiac disease.
- 20 October 2026
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 15
Open AccessRole of gut epithelial-cell derived transglutaminase 2 in the formation of celiac disease autoantibodies
Formation of autoantibodies to transglutaminase 2 (TG2) in celiac disease likely involves TG2-gluten complexes that allow gluten-specific CD4+ T cells to provide help to TG2-specific B cells. To investigate whether TG2 derived from intestinal epithelial cells (IECs) contributes to this process, we generated mice with inducible IEC-specific expression of TG2 fused to a deamidated gluten peptide (DGP) containing a T-cell epitope. Upon induction, the TG2-DGP fusion protein was expressed in IECs and released into the intestinal lumen. In HLA-DQ2.5 transgenic mice with activated gluten-specific CD4+ T cells and naive TG2-specific B cells, expression of TG2-DGP was immunogenic and drove the production of intestinal and systemic anti-TG2 autoantibodies. TG2-specific B cells predominantly expanded in Peyer’s patches, suggesting that their priming and subsequent differentiation into lamina propria TG2-specific IgA+ plasma cells occurs in gut-associated lymphoid tissues. The findings demonstrate immunogenicity of IEC-derived TG2-DGP fusion antigen supporting the notion of a pathogenic role for luminal TG2 in driving anti-TG2 autoimmunity in celiac disease.
- Open Access
Role of gut epithelial-cell derived transglutaminase 2 in the formation of celiac disease autoantibodies
Formation of autoantibodies to transglutaminase 2 (TG2) in celiac disease likely involves TG2-gluten complexes that allow gluten-specific CD4 + T cells to provide help to TG2-specific B cells. To investigate whether TG2 derived from intestinal epithelial cells (IECs) contributes to this process, we generated mice with inducible IEC-specific expression of TG2 fused to a deamidated gluten peptide (DGP) containing a T-cell epitope. Upon induction, the TG2-DGP fusion protein was expressed in IECs and released into the intestinal lumen. In HLA-DQ2.5 transgenic mice with activated gluten-specific CD4 + T cells and naive TG2-specific B cells, expression of TG2-DGP was immunogenic and drove the production of intestinal and systemic anti-TG2 autoantibodies. TG2-specific B cells predominantly expanded in Peyer’s patches, suggesting that their priming and subsequent differentiation into lamina propria TG2-specific IgA + plasma cells occurs in gut-associated lymphoid tissues. The findings demonstrate immunogenicity of IEC-derived TG2-DGP fusion antigen supporting the notion of a pathogenic role for luminal TG2 in driving anti-TG2 autoimmunity in celiac disease. IMPACT STATEMENT: Luminal release of intestinal epithelial cell-derived transglutaminase 2–gluten fusion protein initiates anti-TG2 autoimmunity by linking gluten-specific T-cell help to TG2-specific B cells in Peyer’s patches.
Open AccessRole of gut epithelial-cell derived transglutaminase 2 in the formation of celiac disease autoantibodies
Formation of autoantibodies to transglutaminase 2 (TG2) in celiac disease likely involves TG2-gluten complexes that allow gluten-specific CD4 + T cells to provide help to TG2-specific B cells. To investigate whether TG2 derived from intestinal epithelial cells (IECs) contributes to this process, we generated mice with inducible IEC-specific expression of TG2 fused to a deamidated gluten peptide (DGP) containing a T-cell epitope. Upon induction, the TG2-DGP fusion protein was expressed in IECs and released into the intestinal lumen. In HLA-DQ2.5 transgenic mice with activated gluten-specific CD4 + T cells and naive TG2-specific B cells, expression of TG2-DGP was immunogenic and drove the production of intestinal and systemic anti-TG2 autoantibodies. TG2-specific B cells predominantly expanded in Peyer’s patches, suggesting that their priming and subsequent differentiation into lamina propria TG2-specific IgA + plasma cells occurs in gut-associated lymphoid tissues. The findings demonstrate immunogenicity of IEC-derived TG2-DGP fusion antigen supporting the notion of a pathogenic role for luminal TG2 in driving anti-TG2 autoimmunity in celiac disease. IMPACT STATEMENT: Luminal release of intestinal epithelial cell-derived transglutaminase 2–gluten fusion protein initiates anti-TG2 autoimmunity by linking gluten-specific T-cell help to TG2-specific B cells in Peyer’s patches.
- Open Access
- 19 August 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (20)
IFN-γ is a direct driver of crypt hyperplasia in celiac disease
Crypt hyperplasia is a key feature of celiac disease (CeD) and several other small intestinal inflammatory conditions. Analysis of the gut epithelial crypt zone by mass spectrometry–based tissue proteomics revealed a strong IFN-γ signal in active CeD. This signal, hallmarked by increased expression of MHC molecules, was paralleled by diminished expression of proteins associated with fatty acid metabolism. Crypt hyperplasia and the same proteomic changes were observed in WT mice administered IFN-γ. In mice with conditional KO of the IFN-γ receptor in gut epithelial cells, these signature morphological and proteomic changes were not induced with IFN-γ administration. IFN-γ was thus a driver of crypt hyperplasia in CeD by acting directly on crypt epithelial cells. The results are relevant to other enteropathies with involvement of IFN-γ.
- 19 August 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (20)
Open AccessIFN-γ is a direct driver of crypt hyperplasia in celiac disease
Crypt hyperplasia is a key feature of celiac disease (CeD) and several other small intestinal inflammatory conditions. Analysis of the gut epithelial crypt zone by mass spectrometry–based tissue proteomics revealed a strong IFN-γ signal in active CeD. This signal, hallmarked by increased expression of MHC molecules, was paralleled by diminished expression of proteins associated with fatty acid metabolism. Crypt hyperplasia and the same proteomic changes were observed in WT mice administered IFN-γ. In mice with conditional KO of the IFN-γ receptor in gut epithelial cells, these signature morphological and proteomic changes were not induced with IFN-γ administration. IFN-γ was thus a driver of crypt hyperplasia in CeD by acting directly on crypt epithelial cells. The results are relevant to other enteropathies with involvement of IFN-γ.
- Open Access
- 2 July 2025
- Published by Elsevier in Gastroenterology
- Vol. 169 (7) , 1450-1461
Peyer’s Patch B Cells Sample Transglutaminase-Gluten Complexes and Drive Celiac Disease Autoimmunity
- 2 July 2025
- Published by Elsevier in Gastroenterology
- Vol. 169 (7) , 1450-1461
Open AccessPeyer’s Patch B Cells Sample Transglutaminase-Gluten Complexes and Drive Celiac Disease Autoimmunity
- 17 March 2025
- Published by Wiley in European Journal of Immunology
- Vol. 55 (3) , e202451658
A Mouse Model for Generation of Gut Lamina Propria Plasma Cells Specific for a Deamidated Gluten Peptide
Celiac disease is an autoimmune enteropathy caused by aberrant immune responses to dietary gluten peptides. Plasma cells (PCs) reactive with deamidated gluten peptides (DGP) or transglutaminase 2 are abundant in celiac disease gut lesions, yet their role in disease pathogenesis remains unclear. Here, we present a mouse model that allows for exploring the role of DGP‐specific IgA PCs. This model employs a novel immunoglobulin knock‐in (Ig KI) mouse expressing a celiac‐patient‐derived anti‐DGP B‐cell receptor (BCR) that recognizes an immunodominant DGP epitope. In these mice, ∼80% of splenic B cells express the transgenic BCR. In co‐culture experiments with transgenic DGP‐specific B cells and transgenic gluten‐specific CD4+ T cells, stimulation with DGP led to T‐cell and B‐cell proliferation. Mice carrying the celiac disease‐associated human leukocyte antigen (HLA) allotype HLA‐DQ2.5 developed DGP‐specific small intestinal IgA PCs upon adoptive transfer of HLA‐DQ2.5‐expressing DGP‐specific B cells and oral immunizations with DGP and cholera toxin (CT). However, covalent conjugation of DGP to CT was required for effective anti‐DGP gut immunity. This novel mouse model provides an important tool for studying the role of PCs beyond antibody production in celiac disease.
- 17 March 2025
- Published by Wiley in European Journal of Immunology
- Vol. 55 (3) , e202451658
A Mouse Model for Generation of Gut Lamina Propria Plasma Cells Specific for a Deamidated Gluten Peptide
Celiac disease is an autoimmune enteropathy caused by aberrant immune responses to dietary gluten peptides. Plasma cells (PCs) reactive with deamidated gluten peptides (DGP) or transglutaminase 2 are abundant in celiac disease gut lesions, yet their role in disease pathogenesis remains unclear. Here, we present a mouse model that allows for exploring the role of DGP‐specific IgA PCs. This model employs a novel immunoglobulin knock‐in (Ig KI) mouse expressing a celiac‐patient‐derived anti‐DGP B‐cell receptor (BCR) that recognizes an immunodominant DGP epitope. In these mice, ∼80% of splenic B cells express the transgenic BCR. In co‐culture experiments with transgenic DGP‐specific B cells and transgenic gluten‐specific CD4+ T cells, stimulation with DGP led to T‐cell and B‐cell proliferation. Mice carrying the celiac disease‐associated human leukocyte antigen (HLA) allotype HLA‐DQ2.5 developed DGP‐specific small intestinal IgA PCs upon adoptive transfer of HLA‐DQ2.5‐expressing DGP‐specific B cells and oral immunizations with DGP and cholera toxin (CT). However, covalent conjugation of DGP to CT was required for effective anti‐DGP gut immunity. This novel mouse model provides an important tool for studying the role of PCs beyond antibody production in celiac disease.
Coeliac disease: the paradox of diagnosing a food hypersensitivity disorder with autoantibodies
Serum antibodies to the autoantigen transglutaminase 2 (TG2) are increasingly harnessed to diagnose coeliac disease. Diagnostic guidelines for children give recommendation for a no-biopsy-based diagnosis through detection of high amounts of IgA anti-TG2 antibodies in serum with confirmation of positivity in a separate blood sample by characteristic autoantibody-staining of tissue. While measurement of IgA anti-TG2 also is important in the diagnostic workup of adults, the adult guidelines still mandate examination of gut biopsies. This requirement might well change in the future, as might the necessity for confirming autoantibody positivity by tissue staining. The key role of autoantibody serology for diagnosis of coeliac disease is paradoxical. Coeliac disease was considered, and still can be considered, a food intolerance disorder where autoantibodies at face value are out of place. The immunological mechanisms underlying the formation of autoantibodies in response to gluten exposure have been dissected. This review presents the current insights demonstrating that the autoantibodies in coeliac disease are intimately integrated in the maladapted immune response to gluten.
Coeliac disease: the paradox of diagnosing a food hypersensitivity disorder with autoantibodies
Serum antibodies to the autoantigen transglutaminase 2 (TG2) are increasingly harnessed to diagnose coeliac disease. Diagnostic guidelines for children give recommendation for a no-biopsy-based diagnosis through detection of high amounts of IgA anti-TG2 antibodies in serum with confirmation of positivity in a separate blood sample by characteristic autoantibody-staining of tissue. While measurement of IgA anti-TG2 also is important in the diagnostic workup of adults, the adult guidelines still mandate examination of gut biopsies. This requirement might well change in the future, as might the necessity for confirming autoantibody positivity by tissue staining. The key role of autoantibody serology for diagnosis of coeliac disease is paradoxical. Coeliac disease was considered, and still can be considered, a food intolerance disorder where autoantibodies at face value are out of place. The immunological mechanisms underlying the formation of autoantibodies in response to gluten exposure have been dissected. This review presents the current insights demonstrating that the autoantibodies in coeliac disease are intimately integrated in the maladapted immune response to gluten.
- Open Access
- 3 November 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (11) , e0259082
TG2-gluten complexes as antigens for gluten-specific and transglutaminase-2 specific B cells in celiac disease
A hallmark of celiac disease is the gluten-dependent production of antibodies specific for deamidated gluten peptides (DGP) and the enzyme transglutaminase 2 (TG2). Both types of antibodies are believed to result from B cells receiving help from gluten-specific CD4+T cells and differentiating into antibody-producing plasma cells. We have here studied the collaboration between DGP- and TG2-specific B cells with gluten-specific CD4+T cells using transgenic mice expressing celiac patient-derived T-cell and B-cell receptors, as well as between B-cell transfectants and patient-derived gluten-specific T-cell clones. We show that multivalent TG2-gluten complexes are efficient antigens for both TG2-specific and DGP-specific B cells and allow both types of B cells to receive help from gluten-specific T cells of many different specificities.
- 3 November 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (11) , e0259082
Open AccessTG2-gluten complexes as antigens for gluten-specific and transglutaminase-2 specific B cells in celiac disease
A hallmark of celiac disease is the gluten-dependent production of antibodies specific for deamidated gluten peptides (DGP) and the enzyme transglutaminase 2 (TG2). Both types of antibodies are believed to result from B cells receiving help from gluten-specific CD4+T cells and differentiating into antibody-producing plasma cells. We have here studied the collaboration between DGP- and TG2-specific B cells with gluten-specific CD4+T cells using transgenic mice expressing celiac patient-derived T-cell and B-cell receptors, as well as between B-cell transfectants and patient-derived gluten-specific T-cell clones. We show that multivalent TG2-gluten complexes are efficient antigens for both TG2-specific and DGP-specific B cells and allow both types of B cells to receive help from gluten-specific T cells of many different specificities.
- Open Access
- 1 January 2021
- Published by Oxford University Press (OUP) in ImmunoHorizons
- Vol. 5 (1) , 25-32
Generation of an HLA-DQ2.5 Knock-In Mouse
The human MHC class II molecule HLA-DQ2.5 is implicated in multiple autoimmune disorders, including celiac disease, type 1 diabetes, and systemic lupus erythematosus. The pathogenic contribution of HLA-DQ2.5 in many of these disorders is not fully understood. There is thus a need for an HLA-DQ2.5 humanized mouse model with physiological expression of this MHC molecule that can be integrated into disease models. In this article, we report the generation of an HLA-DQ2.5 knock-in mouse strain on a C57BL/6 background in which sequences encoding the extracellular moieties of mouse MHC class II H2-IAa and H2-IAb1 have been replaced with those of HLA-DQA1*05:01 and HLA-DQB1*02:01. In heterozygous knock-in mice, the expression of HLA-DQ2.5 is superimposable with the expression of H2-IA. This was not the case in a regular untargeted HLA-DQ2.5 transgenic mouse. HLA-DQ2.5 in the knock-in animals is functional for T cell development and for Ag presentation to HLA-DQ2.5–restricted and gluten-specific T cells. Because C57BL/6 mice do not express H2-IEa, the only functional MHC class II molecule in homozygous HLA-DQ2.5 knock-in mice is the knock-in gene product. This alleviates the need for crossing with MHC class II knockout mice to study the isolated function of the MHC transgene. Our novel mouse strain provides an important tool to study the involvement of HLA-DQ2.5 in models of diseases with association to this HLA allotype.
- 1 January 2021
- Published by Oxford University Press (OUP) in ImmunoHorizons
- Vol. 5 (1) , 25-32
Open AccessGeneration of an HLA-DQ2.5 Knock-In Mouse
The human MHC class II molecule HLA-DQ2.5 is implicated in multiple autoimmune disorders, including celiac disease, type 1 diabetes, and systemic lupus erythematosus. The pathogenic contribution of HLA-DQ2.5 in many of these disorders is not fully understood. There is thus a need for an HLA-DQ2.5 humanized mouse model with physiological expression of this MHC molecule that can be integrated into disease models. In this article, we report the generation of an HLA-DQ2.5 knock-in mouse strain on a C57BL/6 background in which sequences encoding the extracellular moieties of mouse MHC class II H2-IAa and H2-IAb1 have been replaced with those of HLA-DQA1*05:01 and HLA-DQB1*02:01. In heterozygous knock-in mice, the expression of HLA-DQ2.5 is superimposable with the expression of H2-IA. This was not the case in a regular untargeted HLA-DQ2.5 transgenic mouse. HLA-DQ2.5 in the knock-in animals is functional for T cell development and for Ag presentation to HLA-DQ2.5–restricted and gluten-specific T cells. Because C57BL/6 mice do not express H2-IEa, the only functional MHC class II molecule in homozygous HLA-DQ2.5 knock-in mice is the knock-in gene product. This alleviates the need for crossing with MHC class II knockout mice to study the isolated function of the MHC transgene. Our novel mouse strain provides an important tool to study the involvement of HLA-DQ2.5 in models of diseases with association to this HLA allotype.
- 28 December 2020
- Published by Wiley in European Journal of Immunology
- Vol. 51 (4) , 1002-1005
Characterization of T‐cell receptor transgenic mice recognizing immunodominant HLA‐DQ2.5‐restricted gluten epitopes
We created a TCR transgenic mouse with CD4+ T cells recognizing the immunodominant DQ2.5‐glia‐ω2 gluten epitope. We show that these cells respond to deamidated gluten feed in vivo and compare them to previously published α2‐ and γ1‐specific mice. These mice may help enlighten key aspects of celiac disease pathogenesis.
- 28 December 2020
- Published by Wiley in European Journal of Immunology
- Vol. 51 (4) , 1002-1005
Characterization of T‐cell receptor transgenic mice recognizing immunodominant HLA‐DQ2.5‐restricted gluten epitopes
We created a TCR transgenic mouse with CD4+ T cells recognizing the immunodominant DQ2.5‐glia‐ω2 gluten epitope. We show that these cells respond to deamidated gluten feed in vivo and compare them to previously published α2‐ and γ1‐specific mice. These mice may help enlighten key aspects of celiac disease pathogenesis.
- Open Access
- 14 November 2019
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 217 (2)
B cell tolerance and antibody production to the celiac disease autoantigen transglutaminase 2
Autoantibodies to transglutaminase 2 (TG2) are hallmarks of celiac disease. To address B cell tolerance and autoantibody formation to TG2, we generated immunoglobulin knock-in (Ig KI) mice that express a prototypical celiac patient–derived anti-TG2 B cell receptor equally reactive to human and mouse TG2. We studied B cell development in the presence/absence of autoantigen by crossing the Ig KI mice to Tgm2−/− mice. Autoreactive B cells in Tgm2+/+ mice were indistinguishable from their naive counterparts in Tgm2−/− mice with no signs of clonal deletion, receptor editing, or B cell anergy. The autoreactive B cells appeared ignorant to their antigen, and they produced autoantibodies when provided T cell help. The findings lend credence to a model of celiac disease where gluten-reactive T cells provide help to autoreactive TG2-specific B cells by involvement of gluten–TG2 complexes, and they outline a general mechanism of autoimmunity with autoantibodies being produced by ignorant B cells on provision of T cell help.
- 14 November 2019
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 217 (2)
Open AccessB cell tolerance and antibody production to the celiac disease autoantigen transglutaminase 2
Autoantibodies to transglutaminase 2 (TG2) are hallmarks of celiac disease. To address B cell tolerance and autoantibody formation to TG2, we generated immunoglobulin knock-in (Ig KI) mice that express a prototypical celiac patient–derived anti-TG2 B cell receptor equally reactive to human and mouse TG2. We studied B cell development in the presence/absence of autoantigen by crossing the Ig KI mice to Tgm2−/− mice. Autoreactive B cells in Tgm2+/+ mice were indistinguishable from their naive counterparts in Tgm2−/− mice with no signs of clonal deletion, receptor editing, or B cell anergy. The autoreactive B cells appeared ignorant to their antigen, and they produced autoantibodies when provided T cell help. The findings lend credence to a model of celiac disease where gluten-reactive T cells provide help to autoreactive TG2-specific B cells by involvement of gluten–TG2 complexes, and they outline a general mechanism of autoimmunity with autoantibodies being produced by ignorant B cells on provision of T cell help.